Tezosentan

DB06558InvestigationalSmall molecule

Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in...

Mechanism: Pharmacologically active on Endothelin-1 receptor and Endothelin receptor type B
Curator reviewed
Primary indication: Investigated for use/treatment in congestive heart failure, liver disease, and heart disease.Curator reviewed
Formula / weight: C₂₇H₂₇N₉O₆S · 605.625 g/mol (avg)
Code names: ACT-050089

Resolves to

Compound

UNII64J9J55263CAS180384-57-0ChEMBLCHEMBL61780PubChem151174

Structure

InChIKeyTUYWTLTWNJOZNY-UHFFFAOYSA-NSMILESCOC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=NC=C(C=C2)C(C)C)N=C(N=C1OCCO)C1=CC(=NC=C1)C1=NNN=N1

Targets

P25101EDNRAP24530EDNRB

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

16+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tezosentan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account